VeritaCell
Developer of a point-of-care surgical kit and associated methodology for rapid autologous skin cell isolation and application. The company focuses on enabling surgeons to extract, isolate and apply a patient’s own viable skin cells onsite (workflow completed in ~30 minutes) to accelerate wound healing, reduce scarring and minimize donor skin requirements. Founded from academic cell-biology research and commercialisation support, the team combines cell-biology expertise with business and go-to-market experience.
Industries
Nr. of Employees
small (1-50)
Products
Surgical kit for point-of-care autologous skin cell isolation
A self-contained medical kit and associated methodology that enables clinicians to harvest a small piece of skin, isolate viable cells onsite, and apply a cell suspension to wounds within a short procedural timeframe.
Surgical kit for point-of-care autologous skin cell isolation
A self-contained medical kit and associated methodology that enables clinicians to harvest a small piece of skin, isolate viable cells onsite, and apply a cell suspension to wounds within a short procedural timeframe.
Services
Partnership development and clinical collaboration
Engagement with surgeons, researchers and industry partners for pilot studies, clinical validation and commercialization planning.
Partnership development and clinical collaboration
Engagement with surgeons, researchers and industry partners for pilot studies, clinical validation and commercialization planning.
Expertise Areas
- Wound healing and skin regeneration
- Autologous cell therapy for dermatologic applications
- Point-of-care clinical workflow development
- Cell biology methodology development
Key Technologies
- Autologous skin cell isolation methods
- Rapid on-site cell processing (30-minute protocols)
- Dermatome-based tissue harvesting
- Cell suspension application for wound treatment